Christine Fox - 05 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: EVP, U.S. Commercial
Issuer ticker: TEVA
Reported as of: 05 Mar 2026
Net transaction value: -$250,940
SEC form: 4
Accepted by SEC: 09 Mar 2026, 16:16:34 UTC
Prior SEC filing: 06 Mar 2026
Next SEC filing: 04 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Christine Fox

Key filing fact

Christine Fox filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 09 Mar 2026.

Key facts

This page summarizes Christine Fox's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Mar 2026, 16:16.

Change

Previous filing in this sequence was filed on 06 Mar 2026.
Current net transaction value: -$250,940.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001998173 Primary reporting owner

Fox Christine

Relationship: EVP, U.S. Commercial
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Christine Fox
Signature date: 09 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +17,819
Change %: +24%
Price
Shares after: 92,829
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F1, F2

TEVA transaction

Ordinary Shares

Sale

Transaction value: $250,940
Shares: -7,924
Change %: -8.5%
Price: $31.67
Shares after: 84,905
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F1, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -17,819
Change %: -25%
Price: $0.000000^*
Shares after: 53,459
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 17,819
Exercise price
Footnotes: F1, F2, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Footnote F3

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

Footnote F4

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F6

Restricted share units were granted on March 5, 2025, with 17,819 vested on March 5, 2026, 17,819 vesting on each of March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029.